Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2017 1
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

2 results
Results by year
Filters applied: . Clear all
Page 1
Therapeutic drug monitoring to individualize the dosing of pazopanib: a pharmacokinetic feasibility study.
de Wit D, van Erp NP, den Hartigh J, Wolterbeek R, den Hollander-van Deursen M, Labots M, Guchelaar HJ, Verheul HM, Gelderblom H. de Wit D, et al. Ther Drug Monit. 2015 Jun;37(3):331-8. doi: 10.1097/FTD.0000000000000141. Ther Drug Monit. 2015. PMID: 25271729 Clinical Trial.
The primary objective of this study was to evaluate the feasibility of pharmacokinetics (PK)-guided individualized dosing to reduce the interpatient variability in pazopanib exposure. ...During the second period, the patients either recei …
The primary objective of this study was to evaluate the feasibility of pharmacokinetics (PK)-guided individualized
Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib.
Lankheet NAG, Desar IME, Mulder SF, Burger DM, Kweekel DM, van Herpen CML, van der Graaf WTA, van Erp NP. Lankheet NAG, et al. Br J Clin Pharmacol. 2017 Oct;83(10):2195-2204. doi: 10.1111/bcp.13327. Epub 2017 Jul 4. Br J Clin Pharmacol. 2017. PMID: 28500677 Free PMC article.
METHODS: A cohort study was performed in patients treated with imatinib, sunitinib or pazopanib of whom follow-up drug levels were measured between August 2012 and April 2016. ...Therapeutic drug monitoring may add to the improvement of e …
METHODS: A cohort study was performed in patients treated with imatinib, sunitinib or pazopanib of whom follow-up drug